Clinical Trial Update: Targeting PD-L1 and TIGIT in Tumors With Tertiary Lymphoid Structures [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating PD-L1 and TIGIT targeting in tumors with tertiary lymphoid structures has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Cancer

Snippet

Sponsor: Gustave Roussy, Cancer Campus, Grand Paris | Conditions: Metastatic Cancer Lung, Advanced Lung Cancer | Phase 2 | Status: WITHDRAWN